Scientists have designed a new strategy to noninvasively track macrophages in tumors in the breast and brain. Macrophages are immune cells that play a crucial role in the immune system, carrying out a number of functions, including clearing out dead cells and digesting microorganisms. These cells are often recruited by cancer to increase resistance to treatment and support tumor growth.
The Ludwig Cancer Research study, led by Davide Croci and Johanna Joyce, also involved their colleague Ruud B. van Heeswijk from the Lausanne University Hospital.
Joyce stated that monitoring tumor-associated macrophages had the potential to substantially improve how various cancers were therapeutically managed. She explains that brain tumors depended on the presence of these immune cells, noting that targeting macrophages would be a good strategy for treatment.
The Joyce laboratory has been looking into the crucial role played by tumor-associated macrophages and other immune cells in tumors for several years. During this time, researchers discovered how resident macrophages of the microglia, brain and monocyte-derived macrophages differentially populate brain metastases and gliomas. Their research has also showed how tumor-associated macrophages contributed to the therapeutic resistance and recurrence of brain tumors.
At the moment, the immune landscape of tumors in the brain (glioma) can only be viewed using a biopsy, which is a highly invasive procedure.
For their study, the researchers injected two different types of nanoparticles into mice models of breast cancer, gliomas and breast-to-brain tumors. Each of these nanoparticles emits a discernible and distinctive signal that can be detected using an MRI.
The scientists showed that these nanoparticles accumulated in tumor-associated macrophages, which afforded them noninvasive and direct means to use multispectral magnetic resonance imaging to find out the location and abundance of these immune cells across tumor geography. The MRI led to the discovery that labeled tumor-associated macrophages accumulated around the malformed and leaky blood vessels caused by tumors.
The researchers note that this finding could have implications for combination therapies being developed to normalize tumor vasculature in order to enhance delivery of drugs. They also discovered that while monocyte-derived macrophages and microglia were found in almost equal numbers in untreated gliomas, monocyte-derived macrophages tended to cluster together away from microglia in tumors that recurred after radiotherapy.
Radiotherapy is a standard glioma treatment while microglia are immune cells found in the central nervous system.
In the report, Joyce noted that the MRI highlighted previously unknown niches for tumor-associated macrophages in dormant, recurrent and untreated gliomas. The study’s findings were reported in the “Science Translational Medicine” journal.
As more information becomes available about what happens inside malignant tumors, the additional insights could give the likes of CNS Pharmaceuticals Inc. (NASDAQ: CNSP) the basis it needs to make major breakthroughs in finding effective treatments to brain cancers.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
